MDxHealth hits testing milestone with prostate cancer epigenetic Dx

ConfirmMDx detects an epigenetic field effect.--Courtesy of MDxHealth

MDxHealth ($MDXH) is celebrating positive results from recent studies of its prostate cancer molecular diagnostic test. The Belgium-based company says its ConfirmMDx test reaffirmed researchers' hopes that its test could produce a more personalized--and accurate--prostate cancer diagnosis when an initial biopsy comes back negative. About 650,000 American men each year experience prostate biopsies that come back negative, even though an estimated 25% of them may still have cancer, MDxHealth estimates. Report